ClinicalTrials.gg
CompletedNCT01882322MapleUpdated Oct 31, 2024

A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects

A Phase 4 interventional study of Prograf and Advagraf in de Novo Liver Transplant Subjects, sponsored by Astellas Pharma Korea, Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2013, registered Jun 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to compare the efficacy and safety between a group that has been on Prograf twice daily therapy but converted to Advagraf once daily therapy and a group that maintained Prograf twice daily therapy.

Read the detailed description

De novo Liver Transplant Recipients will be divided into two groups. Both groups will receive Prograf (Tacrolimus twice daily therapy), and at Month 1 (Week 4) after surgery, Prograf will be converted to Advagraf (modified release Tacrolimus, once daily) in one group, while Prograf therapy will be continued in other group.

02

Conditions studied

  • de Novo Liver Transplant Subjects

Keywords

  • FK506
  • tacrolimus
  • immunosuppressant
03

In context

Lead sponsor

Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject scheduled for liver transplantation from a living donor or brain dead
  • In case of a woman of , a subject with a negative pregnancy test prior to enrollment and who consents to and would practice double throughout the study (Pessary therapy, or rhythm method, or sexual abstinence, surgical sterilization, menopause or otherwise sterile; however, oral contraceptives are excluded.)
  • A subject with terminal hepatic failure for which liver transplant is necessary
  • A subject who understands and is completely aware of the study objective and risks and who submitted a written form on study participation

Exclusion criteria

Exclusion Criteria:

  • A subject who received multiple organ transplants or any previous organ transplant (including re-transplantation of the liver)
  • A subject who had received auxiliary transplant or used the bioartificial liver (cellular system)
  • A subject allergic or resistant to macrolide antibiotics or Tacrolimus
  • A subject who was taking Cyclosporine and Bosentan (Tracleer) that may interact with Tacrolimus, or potassium-sparing diuretics known to possibly cause hyperkalemia (Spironolactone, Triamterene) at screening
  • A subject who requires treatment or systemic chemotherapy from before transplant. However, a subject who received immunosuppressive treatment for less than 1 month prior to transplant to treat underlying hepatic disorder may be enrolled in the study if treatment is discontinued at the time of transplant.
  • A subject with or malignant tumor history within the past 5 years; however, a subject may be enrolled in this study in case of successfully cured for basal cell carcinoma or squamous cell carcinoma of the skin.
  • A subject who suffers severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect Tacrolimus absorption (may be determined at the discretion of the investigator)
  • A subject with any type of substance abuse, psychological disorder, or communication disorder at the discretion of the investigator
  • A subject who is participating in another study or participated within 28 days of the study, or who had received IP or non-registered medication
  • A subject who is pregnant or breastfeeding
  • A subject (transplant recipient) and/or donor who are positive to
  • A subject who cannot comply with the protocol-planned routine visit schedule
  • A subject who is not appropriate for study participation at the discretion of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Advagraf conversion group

    Oral

    Drug: Prograf · Drug: Advagraf

  • Active comparator
    Prograf maintenance group

    Oral

    Drug: Prograf

Interventions

  • oral

    Also known as: Tacrolimus

  • oral

    Also known as: modified release Tacrolimus

06

What researchers measure

Primary outcomes

  1. Incidence of biopsy-confirmed acute rejection

    Acute rejection incidence (%) = Number of subjects with at least one biopsy -confirmed acute rejection / Total number of subjects included in the relevant analysis set \* 100

    Time frame: from Week 4 to Week 24 post-transplant

Secondary outcomes

  1. Incidence of biopsy-confirmed acute rejection

    Time frame: from Week 4 to Week 12 or Week 24

  2. Severity of biopsy-confirmed acute rejection

    Severity guideline is Banff criteria

    Time frame: from Week 4 to Week 12 and Week 24 after liver transplant

  3. Subject survival rate and graft survival rate

    Time frame: from Week 4 to Week 12 and Week 24 after liver transplant

  4. Safety assessed by the incidence of adverse events, vital signs, physical exam. and labo-tests

    Time frame: for 24 weeks after liver transplant

07

Study locations

1 site
  • Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Jan 2017, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2013
First posted
Jun 20, 2013
StartActual
Jan 30, 2013
Primary completionActual
Jan 3, 2017
CompletionActual
Jan 3, 2017
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01882322
Responsible party
Sponsor
First posted
Jun 20, 2013
Start date
Jan 30, 2013
Primary completion
Jan 3, 2017
Completion
Jan 3, 2017
Last update
Oct 31, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion